Meeting
2014 ASCO Annual Meeting
Vemurafenib treatment in patients with BRAF-mutated melanoma failing MEK inhibition with trametinib.
Authors
Helen Gogas
Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
Helen Gogas , Dirk Schadendorf , Reinhard Dummer , Claus Garbe , Celeste Lebbe , Paul D. Nathan , James M. G. Larkin , Andrew Mark Haydon , Dimitris Bafaloukos , Caroline Robert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 9061)
DOI
10.1200/jco.2014.32.15_suppl.9061
Abstract #
9061
Poster Bd #
265
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP).
First Author: Paolo Antonio Ascierto
Poster
2021 ASCO Annual Meeting
Outcomes of BRAF mutant metastatic melanoma (MM) patients (pts) after cessation of targeted therapy (TT) with BRAF or BRAF/MEK inhibitor(i).
First Author: Natalie Jackson
Poster
2020 ASCO Virtual Scientific Program
The impact of BRAF mutation status on clinical outcomes with single-agent PD-1 inhibitor versus combination ipilimumab/nivolumab.
First Author: Vincent The-Luc Ma
Poster
2018 ASCO Annual Meeting
Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM).
First Author: Matthew Dankner